Shopping Cart
Remove All
Your shopping cart is currently empty
Futuximab
Catalog No. T77015 Copy Product Info
Purity: 95%
🥰Excellent
Futuximab is a chimeric monoclonal antibody targeting EGFR, commonly used in combination with zatuximab to form Sym004. Sym004 targets non-overlapping epitopes on EGFR, exhibiting antitumour activity.
Futuximab
Copy Product Info🥰Excellent
Catalog No. T77015
Futuximab is a chimeric monoclonal antibody targeting EGFR, commonly used in combination with zatuximab to form Sym004. Sym004 targets non-overlapping epitopes on EGFR, exhibiting antitumour activity.
Futuximab
Cas No. 1310460-85-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $745 | - | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,770 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.5% (SDS-PAGE); 96.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Futuximab is a chimeric monoclonal antibody targeting EGFR, commonly used in combination with zatuximab to form Sym004. Sym004 targets non-overlapping epitopes on EGFR, exhibiting antitumour activity. |
| In vitro | In NR6M cells, Futuximab (20 µg/mL, 24-48 hours) induced EGFRvIII internalization and caused a slight decrease in EGFRvIII levels [1]. |
| In vivo | In the EGFRwt-expressing parazacco spilurus subsp. spilurus xenograft model, Futuximab (50 mg/kg, intraperitoneal injection, twice weekly for 5 consecutive weeks) demonstrated significant antitumor activity [1]. |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | ERBB1/EGFR/HER1 |
| Molecular Weight | 146.28 kDa |
| Cas No. | 1310460-85-5 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature | Store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Futuximab | purchase Futuximab | Futuximab cost | order Futuximab | Futuximab in vivo | Futuximab in vitro | Futuximab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.